MedPro and Advanced MedTech to develop new passive needlestick injury prevention technologies

NewsGuard 100/100 Score

MedPro Safety Products, Inc. (OTCBB: MPSP), a pioneer in the development and marketing of passive needlestick injury prevention technology, entered into an exclusive agreement with Advanced MedTech (AMT). AMT is wholly owned by Hooman Asbgahi, the inventor of MedPro’s phlebotomy products, marketed by Greiner Bio-One GmbH under its VACUETTE® brand as the VACUETTE® PREMIUM Safety Needle System and VACUETTE® PREMIUM Blood Collection Set.

Under the agreement’s terms, AMT will provide MedPro with R&D, market research, product design and development, engineering and other services as directed by MedPro. MedPro has the first right of refusal to all intellectual property in which Mr. Asbaghi has an interest and products he develops.

“This exclusive agreement with Advanced MedTech solidifies our relationship with one of the leading innovators in passive needlestick injury prevention,” said Walter Waller, MedPro President and COO. “We believe that Mr. Asbaghi’s VACUETTE® fully-passive designs provide healthcare providers with superior needlestick risk management, and with our manufacturing and distribution partner, Greiner Bio-One GmbH, we are very excited to introduce them to the marketplace. We foresee a long and fruitful relationship with Mr. Asbaghi as we work together to develop new passive technologies for our product portfolio.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New tARC-seq method enhances precision in tracking SARS-CoV-2 mutations